These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A. Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005 [Abstract] [Full Text] [Related]
4. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group. J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224 [Abstract] [Full Text] [Related]
8. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure]. Astrup A. Acta Med Austriaca; 1998 Jan; 25(4-5):146-9. PubMed ID: 9879391 [Abstract] [Full Text] [Related]
10. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. Tallett AJ, Blundell JE, Rodgers RJ. Behav Brain Res; 2009 Mar 17; 198(2):359-65. PubMed ID: 19061919 [Abstract] [Full Text] [Related]
11. How does sibutramine work? Lean ME. Int J Obes Relat Metab Disord; 2001 Dec 17; 25 Suppl 4():S8-11. PubMed ID: 11916106 [Abstract] [Full Text] [Related]
12. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. Halford JC, Boyland EJ, Cooper SJ, Dovey TM, Huda MS, Dourish CT, Dawson GR, Wilding JP. J Psychopharmacol; 2010 Jan 17; 24(1):99-109. PubMed ID: 18755818 [Abstract] [Full Text] [Related]
14. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Diabetes Nutr Metab; 2004 Aug 17; 17(4):222-9. PubMed ID: 15575343 [Abstract] [Full Text] [Related]
15. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT. Diabetes Obes Metab; 2005 May 17; 7(3):246-53. PubMed ID: 15811141 [Abstract] [Full Text] [Related]
16. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Sabuncu T, Ucar E, Birden F, Yasar O. Diabetes Nutr Metab; 2004 Apr 17; 17(2):103-7. PubMed ID: 15244102 [Abstract] [Full Text] [Related]
17. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group. Am Heart J; 2001 Sep 17; 142(3):489-97. PubMed ID: 11526363 [Abstract] [Full Text] [Related]